Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | GLA | P06280 | 2/20 | 0.64 |
| ▸ | PNMT | P11086 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30709076 | 1.00 | KDM4E (0.70) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL714973 | 0.85 | KDM4E (0.70) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL559310 | 0.85 | CSNK2A1 (0.51) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL29673212 | 0.85 | CSNK2A1 (0.51) | KDM4EATMTAAR1TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL1467248 | 0.84 | KDM4E (0.68) | KDM4EATMTAAR1TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL8299478 | 0.83 | CSNK2A1 (0.53) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL12841591 | 0.83 | HTR1A (0.48) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL210639 | 0.82 | ATM (1.00) | KDM4EATMTAAR1TSHRMAPK1 | |
| SCHEMBL29351641 | 0.82 | ATM (1.00) | KDM4EATMTAAR1TSHRMAPK1 | |
| Iodide SCHEMBL10518637 | 0.81 | ATM (0.96) | KDM4EATMTAAR1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023202582-A1 | GPCR REGULATOR AND USE THEREOF | 北京昌平实验室 | 2023-10-26 | — | — | WO | disclosed |
| EP-3144303-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9556139-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2826774-B1 | Intermediates for 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20150232442-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2015-08-20 | — | — | US | disclosed |
| US-9096567-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| EP-2826774-A1 | Intermediates for 6-substituted phenoxychroman carboxylic acid derivatives | Array Biopharma, Inc. (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2307397-B1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20140005418-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8569522-B2 | 6-substituted phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2011-05-05 | — | — | US | disclosed |
| EP-2307397-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009158426-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20050065171-A1 | Substituted purine derivatives | ARIAD PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2005009348-A2 | SUBSTITUTED PURINE DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065171-A1 | Substituted purine derivatives | ADORA2A, PNP, HPRT1 | KDM4E 2177/4885ATM 3088/4885TAAR1 617/4885 |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | GPR52, CD22, CD4 | KDM4E 1869/4885ATM 4670/4885TAAR1 337/4885 |
| US-20150232442-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | GPR52, CD22, CD74 | KDM4E 1993/4885ATM 4651/4885TAAR1 426/4885 |
| US-20140005418-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | UGT1A6, UGT2B7, UGT1A7 | KDM4E 3355/4885ATM 4556/4885TAAR1 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.